文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

依维莫司联合挽救性放疗治疗前列腺切除术后生化复发的一期试验

Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-10-20

这项一期研究采用改良3+3剂量递增设计,评估依维莫司联合标准挽救性放疗治疗前列腺切除术后生化复发的安全性和耐受性。未观察到剂量限制性毒性,每日≤10 mg依维莫司联合分次放疗安全可耐受。

要点

  • 依维莫司每日≤10 mg联合前列腺床挽救性放疗未出现剂量限制性毒性。
  • 4例(22.2%)发生3级急性毒性,无3级及以上慢性毒性。
  • 中位随访17.8个月,9例(56.3%)PSA降至不可测最低点,5例(31.3%)出现第二次生化复发。

核心结论

  • 依维莫司每日≤10 mg联合前列腺切除术后分次放疗安全且可耐受。

研究设计与样本

  • 一期研究采用改良3+3剂量递增设计,评估依维莫司联合标准挽救性放疗治疗前列腺切除术后生化复发的安全性和耐受性。
  • 监测急性(≤90天)和慢性(>90天)治疗相关毒性。

主要发现

  • 未观察到剂量限制性毒性。
  • 常见急性治疗相关毒性包括1或2级黏膜炎(55.6%)、1或2级乏力(38.9%)、1或2级皮疹(61.1%)和1级泌尿系统症状(61.1%)。
  • 4例(22.2%)发生3级急性毒性(皮疹、贫血、淋巴细胞减少和中性粒细胞减少各1例),无患者发生3级及以上慢性毒性。
  • 中位随访17.8个月(范围1.2-46.0个月),9例(56.3%)达到不可测PSA最低点,5例(31.3%)出现第二次生化复发。

关键数值与推荐

  • 依维莫司每日剂量≤10 mg与分次放疗联合安全可耐受。
  • 放疗方案为前列腺床37次×1.8 Gy,总剂量66.6 Gy。

临床怎么用

  • 对于前列腺切除术后生化复发患者,每日≤10 mg依维莫司联合挽救性放疗未出现剂量限制性毒性,可考虑作为进一步研究的联合方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In up to half of patients treated with salvage radiation therapy (SRT) for rising prostate-specific antigen levels, a second biochemical recurrence ultimately develops. Phosphatase and tensin homolog inactivation is implicated in prostate cancer progression, and upregulation of the mammalian target of rapamycin pathway can lead to tumor hypoxia and radioresistance. Everolimus is a mammalian target of rapamycin inhibitor with both antitumor and radiosensitizing effects. METHODS AND MATERIALS: We performed a phase 1 study using a modified 3 + 3 dose-escalation design to evaluate the safety and tolerability of everolimus in combination with standard SRT for the treatment of biochemical recurrence following prostatectomy. After a 2-week run-in period of everolimus daily therapy, patients received prostate bed irradiation with daily cone beam computed tomography localization in 37 fractions of 1.8 Gy each (total dose, 66.6 Gy). Patients were monitored for both acute (≤90 days) and chronic (>90 days) treatment-related toxicities. RESULTS: Eighteen patients received everolimus at dose levels of 5 mg (n=6), 7.5 mg (n=6), or 10 mg (n=6) daily in conjunction with SRT. No dose-limiting toxicities were observed. Common acute treatment-related toxicities included grade 1 or 2 mucositis (55.6%), grade 1 or 2 fatigue (38.9%), grade 1 or 2 rash (61.1%), and grade 1 urinary symptoms (61.1%). A grade 3 acute toxicity occurred in 4 patients (22.2%) (n=1 for rash, anemia, lymphopenia, and neutropenia), and no patients had a chronic toxicity of grade 3 or greater. After a median follow-up time of 17.8 months (range, 1.2-46.0 months), an undetectable prostate-specific antigen nadir was achieved in 9 patients (56.3%) and a second biochemical recurrence developed in 5 patients (31.3%). CONCLUSIONS: Everolimus at a dose of ≤10 mg daily appears to be safe and tolerable in combination with fractionated post-prostatectomy radiation therapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Narayan V, Vapiwala N, Mick R, et al. Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy. Int J Radiat Oncol Biol Phys. 2016. PMID: 27986349. doi:10.1016/j.ijrobp.2016.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。